Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Back to research

Alemtuzumab CARE-MS II 5-year follow-up

2017273 citationsJournal Articlehybrid Open Access

Authors

Alasdair Coles · Queen Mary University of London

Jeffrey Cohen · Queen Mary University of London

Edward Fox · Queen Mary University of London

Gavin Giovannoni · Queen Mary University of London

Hans‐Peter Hartung · Queen Mary University of London

Eva Havrdová · Queen Mary University of London

Sven Schippling

Abstract

This study provides Class III evidence that alemtuzumab provides efficacy and slowing of brain atrophy through 5 years.

Topics & Keywords

Multiple Sclerosis Research Studies Rheumatoid Arthritis Research and Therapies Peripheral Neuropathies and Disorders

Publication Details

Published in: Neurology

Volume 89, Issue 11, pp. 1117-1126

DOI: 10.1212/wnl.0000000000004354

Field-Weighted Citation Impact: 25.60

Alemtuzumab CARE-MS II 5-year follow-up | Researchclopedia

· Queen Mary University of London

Krzysztof Selmaj · Queen Mary University of London

Anthony Traboulsee · Queen Mary University of London

D. A. S. Compston · Queen Mary University of London

David Margolin · Queen Mary University of London

Karthinathan Thangavelu · Queen Mary University of London

Madalina Chirieac · Queen Mary University of London

D. Jody · Queen Mary University of London

Panos Xenopoulos · Queen Mary University of London

Richard Hogan · Queen Mary University of London

Michael Panzara · Queen Mary University of London

Douglas L. Arnold · Queen Mary University of London